Company Overview of Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule that completed Phase IIa clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which is in pre-clinical trials for the treatment of type 2 diabetes. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.
Hi-Tech Park 2/4
PO Box 39098
Founded in 2002
Key Executives for Oramed Pharmaceuticals Inc.
Chief Executive Officer, President and Executive Director
Total Annual Compensation: $381.3K
Chief Financial Officer, Treasurer and Secretary
Total Annual Compensation: $193.8K
Chief Operating Officer and Vice President of Business Development
Total Annual Compensation: $199.2K
Chief Scientific Officer and Director
Total Annual Compensation: $271.3K
Compensation as of Fiscal Year 2014.
Oramed Pharmaceuticals Inc. Key Developments
Oramed Completes Randomization of over 50% of Patients in Phase IIb Oral Insulin Study
Sep 9 15
Oramed Pharmaceuticals Inc. announced that 98 patients have already been enrolled in the Company's Phase IIb study of its oral insulin capsule, ORMD-0801, which represents more than 50% of the 180 patients expected to be recruited for the trial. The double-blind, randomized Phase IIb study for type 2 diabetes was initiated on June 30 and is designed to generate ample data for both efficacy and safety endpoints.
Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 11, 2015
Jul 7 15
Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 11, 2015., at 11:00 US Eastern Standard Time. Location: offices of Sullivan & Worcester LLP. Agenda: To re-elect six directors of the Company to hold office until next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal; to ratify the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the 2015 fiscal year; and to transact any other business as may properly come before the Annual Meeting or any adjournments thereof.
Oramed Pharmaceuticals Agrees to Investment and License Agreement in China with Sinopharm Capital Management Co. Ltd. and Hefei Life Science & Technology Park Investments and Development Co., Ltd
Jul 7 15
Oramed Pharmaceuticals announced that it agreed to an investment and license agreement in China with Sinopharm Capital Management Co. Ltd. and Hefei Life Science & Technology Park Investments and Development Co. Ltd. for $50 million plus royalty payments. Under the terms of the agreement, Sinopharm and Hefei will acquire a 10% stake in Oramed Pharma for $12 million and exclusive rights for oral insulin capsule ORMD-0801 for $38 million. Of the $38 million, $18 million will be paid once the license agreement is signed and the remaining $20 million will be paid once results are released for Oramed's ongoing Phase IIb trial in the U.S. Sinopharm and Hefei will also pay a 10% royalty on sales.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 2, 2015
November 3, 2014
Most Searched Private Companies
Sponsored Financial Commentaries